USPTO serial 79268366
NEUVIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- DANTZLER, LAUREN ALEXANDRIA
- Law office
- TMO LAW OFFICE 129 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with NEUVIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charles G. Zug
Charles G. Zug Nelson Mullins Riley & Scarborough LLP301 S. College St.Suite 2300, IP DepartmentCharlotte, NC 28202Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, pharmaceutical preparations for prevention, management or treatment of inflammatory disorders, neurological disorders, psychiatric disorders, malignancy, immune disorders, metabolic disorders, infectious diseases, gastrointestinal disorders, cardiovascular disorders, cancer, pain; Pharmaceutical preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavior modification, schizophrenia, bi-polar disorder, pain; Veterinary preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Plant extracts for medical, pharmaceutical and veterinary use; Biochemical and biological products, in the nature of terpenophenolics, terpenoids and flavones for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Biochemical and biological products, namely, terpenophenolics, terpenoids and flavones for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical preparations for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical preparations for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Analgesic preparations; Anti-inflammatory preparations; Anti-microbial preparations for inhibiting microbiological growth and infection in medical and veterinary situations; Anti-nauseants treatment preparations; Anti-spasmodics; Anticonvulsants; Appetite stimulant preparations for medical purposes; Nausea medications, namely, nausea treatment preparations | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 27, 2023 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 4, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 4, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 4, 2022 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 4, 2022 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 4, 2022 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 21, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 15, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 14, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 14, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 14, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 14, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 14, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 20, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 9, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 9, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 9, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 3, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 3, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 26, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 9, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 28, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 25, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 24, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 17, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 25, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 8, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 4, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 26, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |